IONIS PHARMACEUTICALS INC 4

Director Ludwig Hantson received an award of 3,399 Ionis Pharmaceuticals RSUs, increasing his direct holdings to 3,399 common shares.

On July 15, 2026, Ionis Pharmaceuticals director Ludwig Hantson received a grant of 3,399 Restricted Stock Units (RSUs) under the company’s Amended and Restated 2002 Non-Employee Directors' Stock Option Plan, representing a contingent right to receive an equal number of Ionis common shares or their cash equivalent upon vesting. The RSUs vest in three equal annual installments beginning July 15, 2027 and will be fully vested by July 15, 2029, with no portion vested as of the grant date. This is a routine equity compensation award rather than an open-market purchase or sale. Based on the filing, his direct ownership in Ionis common stock increased by 3,399 shares to a total of 3,399 shares following this grant; without a disclosed market price, the dollar value of both the grant and his post-transaction holdings cannot be precisely estimated from the filing alone.

Filing Facts

CIK

874015

Ticker

IONS

Form

4

Source Type

fda

Accession

0000874015-26-000246

Alert Tier

5